Thus, the administration of IL-20 antibody in myocardial reperfusion, either by thrombolytic medication or using percutaneous coronary intervention, to repress myocardial ischemia-reperfusion injury could be a promising novel strategy for the improvement of AMI treatment. Here, IL20 is linked to myocardial ischemia.